This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of blaKPC-53, located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively. The present findings provide new insights into the mechanisms of resistance to ceftazidime-avibactam.
KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam / Di Pilato V.; Aiezza N.; Viaggi V.; Antonelli A.; Principe L.; Giani T.; Luzzaro F.; Rossolini G.M.. - In: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. - ISSN 0066-4804. - ELETTRONICO. - 65:(2021), pp. e01429-20-e01429-20. [10.1128/AAC.01429-20]
KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam
Di Pilato V.;Aiezza N.;Antonelli A.;Giani T.;Rossolini G. M.
2021
Abstract
This study reports on the characterization of a Klebsiella pneumoniae clinical isolate showing high-level resistance to ceftazidime-avibactam associated with the production of KPC-53, a KPC-3 variant exhibiting a Leu167Glu168 duplication in the Ω-loop and a loss of carbapenemase activity. Whole-genome sequencing (WGS) revealed the presence of two copies of blaKPC-53, located on a pKpQIL-like plasmid and on a plasmid prophage of the Siphoviridae family, respectively. The present findings provide new insights into the mechanisms of resistance to ceftazidime-avibactam.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
